NYSE:HRC - Hill-Rom Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $121.80
  • Forecasted Upside: 8.53 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.04 (-0.04%)

This chart shows the closing price for HRC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hill-Rom Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRC

Analyst Price Target is $121.80
▲ +8.53% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Hill-Rom in the last 3 months. The average price target is $121.80, with a high forecast of $130.00 and a low forecast of $115.00. The average price target represents a 8.53% upside from the last price of $112.23.

This chart shows the closing price for HRC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Hill-Rom. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2021Raymond JamesBoost Price TargetOutperform$120.00 ➝ $122.00Medium
5/3/2021Robert W. BairdBoost Price TargetOutperform$115.00 ➝ $125.00Low
2/16/2021Raymond JamesBoost Price TargetOutperform$113.00 ➝ $120.00Low
2/8/2021Raymond JamesBoost Price TargetOutperform$107.00 ➝ $113.00Low
2/8/2021Morgan StanleyBoost Price TargetOverweight$125.00 ➝ $130.00Medium
2/8/2021Robert W. BairdBoost Price TargetOutperform$105.00 ➝ $115.00Medium
12/15/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $125.00Low
11/9/2020Raymond JamesBoost Price TargetOutperform$100.00 ➝ $107.00Medium
11/4/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
10/12/2020Raymond JamesLower Price TargetOutperform$115.00 ➝ $100.00High
10/1/2020KeyCorpLower Price TargetOverweight$138.00 ➝ $115.00Medium
9/29/2020Needham & Company LLCLower Price TargetBuy$129.00 ➝ $117.00Medium
9/21/2020Morgan StanleyLower Price TargetOverweight$112.00 ➝ $110.00Medium
9/16/2020Raymond JamesReiterated RatingBuyLow
9/1/2020Robert W. BairdInitiated CoverageOutperform$115.00High
8/3/2020Morgan StanleyLower Price TargetOverweight$123.00 ➝ $112.00High
8/3/2020Raymond JamesLower Price TargetOutperform$120.00 ➝ $115.00Medium
8/3/2020KeyCorpLower Price TargetOverweight$140.00 ➝ $138.00Medium
7/31/2020Needham & Company LLCLower Price TargetBuy$131.00 ➝ $129.00Low
5/4/2020UBS GroupLower Price TargetBuy$130.00 ➝ $125.00High
4/14/2020BarclaysReiterated RatingBuy$125.00Medium
3/27/2020Morgan StanleyLower Price TargetOverweight$138.00 ➝ $125.00Low
3/17/2020BarclaysUpgradeEqual Weight ➝ Overweight$116.00High
1/24/2020Needham & Company LLCReiterated RatingBuy$131.00High
12/17/2019Morgan StanleyUpgradeEqual ➝ Equal Weight$113.00 ➝ $138.00High
8/6/2019BarclaysBoost Price TargetEqual Weight$108.00 ➝ $116.00High
8/6/2019Needham & Company LLCReiterated RatingBuy$125.00High
8/5/2019KeyCorpBoost Price TargetOverweight$114.00 ➝ $125.00High
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$103.00 ➝ $108.00Low
3/11/2019Needham & Company LLCReiterated RatingBuy$116.00Low
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$100.00 ➝ $98.00Medium
11/27/2018UBS GroupInitiated CoverageBuy$115.00High
11/5/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$100.00 ➝ $105.00Low
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$95.00High
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$95.00 ➝ $100.00Medium
7/31/2018Northcoast ResearchReiterated RatingBuy$104.00Low
7/30/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$97.00 ➝ $100.00Low
7/17/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$97.00 ➝ $115.00High
4/30/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00 ➝ $106.00Medium
4/4/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$85.00Low
1/26/2018Needham & Company LLCReiterated RatingBuyLow
1/18/2018KeyCorpReiterated RatingBuy$97.00Low
1/16/2018Needham & Company LLCReiterated RatingPositive ➝ Buy$90.00 ➝ $105.00Medium
1/10/2018BarclaysReiterated RatingBuy$100.00Low
1/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$94.00High
1/2/2018Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
12/21/2017KeyCorpReiterated RatingBuy$94.00Low
11/29/2017Stifel NicolausReiterated RatingBuy$92.00Low
11/22/2017Bank of AmericaReiterated RatingHoldN/A
11/6/2017BarclaysBoost Price TargetOverweight$86.00 ➝ $90.00N/A
11/6/2017Stifel NicolausBoost Price TargetBuy$84.00 ➝ $85.00N/A
11/6/2017Needham & Company LLCLower Price TargetBuy$93.00 ➝ $90.00N/A
11/5/2017KeyCorpReiterated RatingBuy$82.00 ➝ $89.00N/A
10/17/2017KeyCorpReiterated RatingBuy$82.00N/A
7/30/2017Stifel NicolausReiterated RatingBuy$84.00Low
7/28/2017Cantor FitzgeraldSet Price TargetHold$86.00Low
7/28/2017Needham & Company LLCLower Price TargetBuy$95.00 ➝ $93.00Low
6/30/2017Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $90.00Low
6/29/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$95.00Low
6/29/2017Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$86.00Low
6/9/2017BarclaysBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $86.00Low
5/1/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$70.00 ➝ $84.00Low
5/1/2017BarclaysBoost Price TargetBuy$75.00 ➝ $80.00Low
4/19/2017BarclaysBoost Price TargetOverweight$70.00 ➝ $75.00Low
2/8/2017BarclaysInitiated CoverageOverweight$70.00N/A
1/23/2017Stifel NicolausInitiated CoverageBuy$70.00N/A
6/23/2016KeyCorpReiterated RatingBuy$59.00N/A
(Data available from 6/21/2016 forward)
Hill-Rom logo
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising non-invasive devices that provide respiratory support and assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include tables, lights, and pendants; and positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells and rents products to acute and extended care facilities through direct sales force and distributors; sells and rents products directly to patients in the home; and sells products to primary care facilities through distributors. Hill-Rom Holdings, Inc. was founded in 1915 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $112.23
Low: $111.26
High: $113.28

50 Day Range

MA: $111.91
Low: $108.25
High: $116.66

52 Week Range

Now: $112.23
Low: $80.31
High: $117.68


325,828 shs

Average Volume

411,972 shs

Market Capitalization

$7.46 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Hill-Rom?

The following sell-side analysts have issued stock ratings on Hill-Rom in the last twelve months: KeyCorp, Morgan Stanley, Needham & Company LLC, Raymond James, and Robert W. Baird.
View the latest analyst ratings for HRC.

What is the current price target for Hill-Rom?

5 Wall Street analysts have set twelve-month price targets for Hill-Rom in the last year. Their average twelve-month price target is $121.80, suggesting a possible upside of 8.5%. Morgan Stanley has the highest price target set, predicting HRC will reach $130.00 in the next twelve months. KeyCorp has the lowest price target set, forecasting a price of $115.00 for Hill-Rom in the next year.
View the latest price targets for HRC.

What is the current consensus analyst rating for Hill-Rom?

Hill-Rom currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HRC will outperform the market and that investors should add to their positions of Hill-Rom.
View the latest ratings for HRC.

What other companies compete with Hill-Rom?

How do I contact Hill-Rom's investor relations team?

Hill-Rom's physical mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company's listed phone number is 312-819-7200 and its investor relations email address is [email protected] The official website for Hill-Rom is www.hill-rom.com.